First Aid Shot Therapy (dba First Aid Beverages) develops and commercializes a portfolio of over-the-counter pharmaceutical products delivered in 40ml liquid 'shot' format, including pain, hangover relief, heartburn and cold relief. The company is led by founder and CEO Mary Page Platerink. It has secured distribution with grocery and convenience distributors such as McLane’s, AMI (Core-Mark) and United Grocers, and placement at retailers including HEB, Kum & Go, Circle K Southwest, United Pacific, EZ Mart, Holiday, Tedeschi’s, Schnucks and Safeway. More recently, CVS, Rite Aid and 7-Eleven were added as retail partners. The company completed a $24M Series C financing and plans to use the proceeds to expand its product portfolio. No revenue or user metrics were disclosed in the article. First Aid Shot Therapy (F.A.S.T.) is a Burlingame, California consumer healthcare company led by founder and CEO Mary Page Platerink. The company develops and commercializes over-the-counter (OTC) pharmaceutical products in a 40ml / 1.35oz liquid shot format. Its products are formulated by its proprietary research and development organization, F.A.S.T. Labs. F.A.S.T. currently markets OTC liquid “shot” products and is working to expand its portfolio. The company intends to use the proceeds from its recent financing to bring a second product, F.A.S.T. Upset Stomach Relief, to market. Funds will also support geographic launches in the Boston area and other major U.S. markets nationwide. First Aid Shot Therapy is a Burlingame, California-based consumer healthcare company that produces over-the-counter (OTC) therapies in 40ml/1.35oz single-serve liquid “shot” form. Its core products are OTC pharmaceutical-based single-serve liquids formulated to meet applicable OTC monographs and intended to treat everyday conditions such as pain and upset stomach. The company is led by founder and CEO Mary Page Platerink and was co-founded by Professor Jay Pasricha, M.D. It is developing additional products aimed at a broad range of consumer needs. First Aid Shot Therapy completed a Series A financing led by new investor Sofinnova Ventures; the amount was not disclosed. The company intends to use the funds to support a U.S. product launch beginning in the summer of 2013.

Total raised

$24M

Funding rounds

3

Latest round

Series C

Latest activity

Nov 2015